EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis

Malak A Hassan, Abdelaziz A Awad, Ahmed Marey, Ahmed Mostafa Amin, Ahmed Elshahat, Mohamed El-Moslemani, Ahmed Mansour, Shrouk Ramadan, Mohamed A Aldemerdash

Neurological Sciences · 2025

DOI: 10.1007/s10072-025-08185-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neurological Sciences, 2025. Verfasst von Malak A Hassan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Alexandria University, Alexandria, Egypt. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Pyrrolidinones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al-Azhar University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brivaracetam is a novel third-generation antiseizure medication and an analog of levetiracetam with selective affinity for synaptic vesicle protein 2A (SV2A). By binding SV2A, brivaracetam decreases pre-synaptic neurotransmitter release.

Aim

We aimed to assess the safety and efficacy of brivaracetam in pediatric epilepsy.

Method

We searched PubMed, Scopus, and Web of Science (WOS) for relevant clinical and observational studies from inception until February 2024. We carried out statistical analysis using Open Meta-Analyst. Dichotomous data were pooled as proportions with a 95% confidence interval (CI).

Results

Eleven studies with a total of 805 patients were identified. The analysis of four studies revealed the more than 50% responder rate in a cohort of 252 focal epilepsy patients to be 51.5% (95% CI: [32.6%, 70.5%]). The analysis of three studies involving a cohort of 266 patients found a 20.7% incidence (95% CI: [15.8%, 25.6%]) of complete seizure freedom. The analysis of nine studies involving a cohort of 737 epilepsy patients revealed a retention rate of 66% (95% CI: [40%, 92%]).

Conclusion

This study highlights the efficacy, tolerability, and safety of brivaracetam as adjunctive therapy in pediatric patients with epilepsy. The findings support its consideration as a valuable treatment option for children and adolescents, particularly those with drug-resistant epilepsy. Further trials with longer follow-up durations are needed to study the optimal doses and explore factors affecting drug response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsyPyrrolidinonesHumansChildDrug Therapy, CombinationAdolescent

Stichwörter der Autor:innen

BrivaracetamEpilepsyLevetiracetamSystematic review

Substanzen

brivaracetamAnticonvulsantsPyrrolidinones

Autor:innen und Institutionen

  • Faculty of Medicine, Alexandria University, Alexandria, Egypt.
  • Faculty of Medicine, Al-Azhar University, Cairo, Egypt. awad.abdelaziz.0505@gmail.com.
  • Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
  • Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Faculty of Medicine, Sohag University, Cairo, Egypt.

Förderung

  • Al-Azhar University

Zitieren

APA

Hassan, M. A., Awad, A. A., Marey, A., Amin, A. M., Elshahat, A., El-Moslemani, M., Mansour, A., Ramadan, S., & Aldemerdash, M. A. (2025). Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis. Neurological Sciences. https://doi.org/10.1007/s10072-025-08185-9

Vancouver

Hassan MA, Awad AA, Marey A, Amin AM, Elshahat A, El-Moslemani M, et al. Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis. Neurological Sciences. 2025. doi:10.1007/s10072-025-08185-9

BibTeX
@article{Hassan2025,
  author = {Hassan, Malak A and Awad, Abdelaziz A and Marey, Ahmed and Amin, Ahmed Mostafa and Elshahat, Ahmed and El-Moslemani, Mohamed and Mansour, Ahmed and Ramadan, Shrouk and Aldemerdash, Mohamed A},
  title = {Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis},
  journal = {Neurological Sciences},
  year = {2025},
  doi = {10.1007/s10072-025-08185-9}
}
Kostenlos starten →